Compare Charles River Laboratories Intl. Inc (CRL) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs ProShares Ultra QQQ ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while ProShares Ultra QQQ ETF trades at $93.12. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| CRL | QLD | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $233.60 | $100.53 |
52-Week Low | $145.57 | $57.16 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
QLD, the ProShares Ultra QQQ ETF, trades at $90.13, down 3.81% over 24 hours, reflecting a bearish technical signal with key support at $87. As a 2x daily leveraged ETF tracking the Nasdaq-100, it offers amplified exposure to large-cap tech stocks but carries inherent volatility risks. Recent news highlights its long-term performance, with over 10,000% total return since inception, though comparisons with 3x leveraged alternatives underscore drawdown vulnerabilities.
The outlook for QLD hinges on Nasdaq-100 momentum, with tech earnings and AI optimism as potential catalysts. However, leveraged decay and market volatility pose significant risks, making it suitable only for tactical, risk-tolerant investors. Current neutral oscillators suggest near-term consolidation, but bearish moving averages indicate downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
